Heteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central India

Simple item page
dc.contributor.authorDesikan†, Prabhaen_US
dc.contributor.authorPanwalkar, Nikitaen_US
dc.contributor.authorPunde, Ram Prakashen_US
dc.contributor.authorKhan, Zebaen_US
dc.contributor.authorPauranik, Ankuren_US
dc.contributor.authorMirza, Shaina Begen_US
dc.contributor.authorChourey, Manjuen_US
dc.contributor.authorAnand, Sridharen_US
dc.contributor.authorSachdeva, K.S.en_US
dc.date.accessioned2023-08-19T04:51:47Z
dc.date.available2023-08-19T04:51:47Z
dc.date.issued2023-03
dc.description.abstractBackground & objectives: A combination of resistant and susceptible Mycobacterium tuberculosis (MTB) isolated from clinical specimens is referred to as heteroresistance. Heteroresistance leads to difficulties in drug resistance testing and may adversely affect treatment outcomes. The present study estimated the proportion of heteroresistance among MTB in clinical samples of presumptive drug-resistant tuberculosis (TB) patients in Central India. Methods: A retrospective analysis of data generated from line probe assay (LPA) at a tertiary care hospital in Central India between January 2013 and December 2018 was carried out. A heteroresistant MTB in a sample was indicated by the presence of both wild-type and mutant-type patterns on an LPA strip. Results: Data analysis was carried out on interpretable 11,788 LPA results. Heteroresistance in MTB was detected in 637 (5.4%) samples. Of these, heteroresistance in MTB was detected in 413 (64.8%), 163 (25.5%) and 61 (9.5%) samples with respect to rpoB, katG and inhA genes, respectively. Interpretation & conclusions: Heteroresistance is considered a preliminary step in the development of drug resistance. Delayed or suboptimal anti-tubercular therapy in patients with heteroresistance of MTB may elicit full clinical resistance and negatively impact the National TB Elimination Programme. Further studies are, however, needed to determine the impact of heteroresistance on treatment outcomes in individual patients.en_US
dc.identifier.affiliationsDepartment of Microbiology, †ICMR-Bhopal Memorial Hospital & Research Centre, Bhopal, Madhya Pradeshen_US
dc.identifier.affiliationsWorld Health Organization & 3Central TB Division, Ministry of Health & Family Welfare, New Delhi, Indiaen_US
dc.identifier.citationDesikan† Prabha, Panwalkar Nikita, Punde Ram Prakash, Khan Zeba, Pauranik Ankur, Mirza Shaina Beg, Chourey Manju, Anand Sridhar, Sachdeva K.S.. Heteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central India. Indian Journal of Medical Research. 2023 Mar; 157(2-3): 174-182en_US
dc.identifier.issn0971-5916
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223521
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber2-3en_US
dc.relation.volume157en_US
dc.source.urihttps://doi.org/10.4103/ijmr.ijmr_607_22en_US
dc.subjectCentral Indiaen_US
dc.subjectheteroresistanceen_US
dc.subjectpresumptive drug resistanceen_US
dc.subjecttuberculosisen_US
dc.titleHeteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central Indiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMR2023v157n2-3p174.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research